

RESEARCH ARTICLE

Choice of the initial antiretroviral treatment for HIV-positive individuals in the era of integrase inhibitors


Belén Alejos^{1☯*}, Inés Suárez-García^{2,3☯*}, Otilia Bisbal⁴, José Antonio Iribarren⁵, Víctor Asensi⁶, Miguel Górgolas⁷, Roberto Muga⁸, Santiago Moreno⁹, Inma Jarrín¹, CoRIS cohort^{1†}

1 Centro Nacional de Epidemiología, Instituto de Salud Carlos III, Madrid, Spain, **2** Infectious Diseases Unit, Department of Internal Medicine, Hospital Universitario Infanta Sofía, Madrid, Spain, **3** Universidad Europea, Madrid, Spain, **4** Hospital Universitario Doce de Octubre, Madrid, Spain, **5** Hospital Universitario de Donostia, Donostia, Spain, **6** Hospital Universitario Central de Asturias, Oviedo, Spain, **7** Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain, **8** Hospital Universitari Germans Trias i Pujol, Badalona, Spain, **9** Hospital Universitario Ramón y Cajal-IRYCIS, Madrid, Spain

☯ These authors contributed equally to this work.

†† The complete membership of the author group can be found in the Acknowledgments.

* balejos@isciii.es(BA); inessuarez@hotmail.com (ISG)



OPEN ACCESS

Citation: Alejos B, Suárez-García I, Bisbal O, Iribarren JA, Asensi V, Górgolas M, et al. (2019) Choice of the initial antiretroviral treatment for HIV-positive individuals in the era of integrase inhibitors. PLoS ONE 14(8): e0221598. <https://doi.org/10.1371/journal.pone.0221598>

Editor: Robert Güerri-Fernández, Institut Hospital del Mar d'Investigacions Mediques, SPAIN

Received: June 14, 2019

Accepted: August 10, 2019

Published: August 26, 2019

Copyright: © 2019 Alejos et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: The authors confirm that, for approved reasons, some access restrictions apply to the data underlying the findings. Data cannot be made publicly available because they are owned by a third party, the AIDS Research Network (RIS), and because participants agreed that data would only be used for research projects by RIS or those projects approved by its Executive and Scientific Committee. Interested readers may send requests for the data to proyectoscoris@gmail.com. Requests will be

Abstract

Background

We aimed to describe the most frequently prescribed initial antiretroviral therapy (ART) regimens in recent years in HIV-positive persons in the Cohort of the Spanish HIV/AIDS Research Network (CoRIS) and to investigate factors associated with the choice of each regimen.

Methods

We analyzed initial ART regimens prescribed in adults participating in CoRIS from 2014 to 2017. Only regimens prescribed in >5% of patients were considered. We used multivariable multinomial regression to estimate Relative Risk Ratios (RRRs) for the association between sociodemographic and clinical characteristics and the choice of the initial regimen.

Results

Among 2874 participants, abacavir(ABC)/lamivudine(3TC)/dolutegavir(DTG) was the most frequently prescribed regimen (32.1%), followed by tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC)/elvitegravir(EVG)/cobicistat(COBI) (14.9%), TDF/FTC/rilpivirine (RPV) (14.0%), tenofovir alafenamide (TAF)/FTC/EVG/COBI (13.7%), TDF/FTC+DTG (10.0%), TDF/FTC+darunavir/ritonavir or darunavir/cobicistat (bDRV) (9.8%) and TDF/FTC+raltegravir (RAL) (5.6%).

Compared with ABC/3TC/DTG, starting TDF/FTC/RPV was less likely in patients with CD4<200 cells/μL and HIV-RNA>100.000 copies/mL. TDF/FTC+DTG was more frequent in those with CD4<200 cells/μL and HIV-RNA>100.000 copies/mL. TDF/FTC+RAL and TDF/

assessed by the Executive and Scientific Committee.

Funding: The RIS cohort (CoRIS) is supported by the Instituto de Salud Carlos III through the Red Temática de Investigación Cooperativa en Sida (RD06/006, RD12/0017/0018 and RD16/0002/0006) as part of the Plan Nacional I+D+i and cofinanced by ISCIII-Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER). This study was funded by ViiV Healthcare. ViiV Healthcare was given the opportunity to review a preliminary version of this manuscript for factual accuracy. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The authors are solely responsible for final content and interpretation of the results.

Competing interests: IJ has received teaching fees from ViiV Healthcare and has been an external evaluator of scientific projects for GILEAD. ISG has received conference grants or speaker fees from Bristol-Myers Squibb, ViiV Healthcare, Merck Sharp & Dohme and Gilead. SM has been involved in speaking activities and has received grants for research from Abbott, Boehringer & Ingelheim, Bristol-Myers Squibb, Gilead, Glaxo Smith Kline, Janssen Cilag, Merck Sharp & Dohme, Pfizer, Roche, and Schering Plough. All other authors declare no conflict of interest. This does not alter our adherence to PLOS ONE policies on sharing data and materials.

FTC+bDRV were also more frequent among patients with CD4<200 cells/ μ L and with transmission categories other than men who have sex with men. Compared with ABC/3TC/DTG, the prescription of other initial ART regimens decreased from 2014–2015 to 2016–2017 with the exception of TDF/FTC+DTG. Differences in the choice of the initial ART regimen were observed by hospitals' location.

Conclusions

The choice of initial ART regimens is consistent with Spanish guidelines' recommendations, but is also clearly influenced by physician's perception based on patient's clinical and socio-demographic variables and by the prescribing hospital location.

Introduction

International and local guidelines for the treatment of HIV-infection provide recommendations on the preferred drug combinations for initial antiretroviral therapy (ART) of treatment-naïve patients [1,2]. Although there is a wide range of highly effective and well tolerated therapies, most recent guidelines in Spain and the United States have limited preferred options to integrase inhibitor-based regimens based on the results of clinical trials as well as on the advantages of individual drugs [3,4]. Other guidelines such as the ones from the European AIDS Clinical Society also include regimens based on rilpivirine and boosted darunavir as preferred [2]. Some experts and clinicians feel that current recommendations might be too restrictive and regimens other than those based on integrase inhibitors would be at least as good choices to initiate therapy in most patients.

Previous studies have shown that the decision on what specific ART regimen is prescribed to each patient can be influenced by a variety of factors, not only dependent on the patient (such as comorbidities, HIV stage, concerns about toxicity or drug interactions, risk of nonadherence, patient's preference) but also on the prescribing physician (such as HIV treatment experience, budget limitations, hospital's characteristics, physician's preference) [5,6]. The few studies that have investigated the factors influencing the choice of initial ART were published before newer drugs such as rilpivirine and integrase inhibitors were widely used [5,7–9], and there is no evidence on the factors that could influence the choice of ART with the more recent treatment regimens, and specifically with those including an integrase inhibitor.

In this study, we aimed to describe the most frequently prescribed initial ART regimens in recent years in HIV-positive patients in the Cohort of the Spanish HIV/AIDS Research Network (CoRIS) and to investigate factors associated with the choice of initial ART.

Methods

Study design

CoRIS is an open, multicentre, prospective cohort of ART-naïve HIV-positive adults recruited in 45 centres from 13 of the 17 Autonomous Regions of Spain. Patients are followed periodically in accordance with routine clinical practice. Data are subject to internal quality control. A complete description of the cohort has been published elsewhere [10,11].

Study population

Patients included were antiretroviral-naïve, aged ≥ 18 years, and had started ART between 1st September 2014 (when DTG became available in Spain) and 30th November 2017 with the most commonly used first-line antiretroviral regimens. In order to facilitate the analyses, only regimens prescribed in $>5\%$ of individuals were considered. Patients with no follow-up after initiation of ART were excluded.

Definition of variables

The primary endpoint was the choice of the initial ART according to the most frequently prescribed regimens: abacavir (ABC) /lamivudine (3TC) /dolutegavir (DTG) was the most frequently prescribed ART, followed by tenofovir disoproxil fumarate (TDF) /emtricitabine (FTC)/ elvitegravir (EVG)/ cobicistat (COBI), TDF/FTC/rilpivirine (RPV), tenofovir alafenamide(TAF)/FTC/EVG/COBI, TDF/FTC+DTG, TDF/FTC+darunavir/ritonavir or darunavir/cobicistat (bDRV) and TDF/FTC+raltegravir (RAL).

Possible explanatory variables included sex (male, female), age at ART initiation (<30 , $30-49$, ≥ 50 years), transmission category (men who have sex with men [MSM], heterosexual, injecting drug use, other, unknown), educational level (no education or compulsory education, upper secondary or university education, unknown), origin (Spain, immigrants, unknown), CD4 T-cell count (<200 , ≥ 200 cells/ μL , unknown) and viral load ($\leq 100,000$, $>100,000$ copies/mL, unknown), presence of hepatitis C virus antibodies (no, yes, unknown), presence of hepatitis B virus surface antigen (HBVSA) (no, yes, unknown), triglycerides (≤ 150 , >150 mg/dL, unknown), HDL (≤ 40 , >40 mg/dL, unknown) and total cholesterol (≤ 200 , >200 mg/dL, unknown) within 6 months previous to ART initiation, AIDS diagnosis at ART initiation (no, yes), presence of comorbidities (cardiovascular, nephrology, neurologic [no, yes]), period of ART initiation (2014–2015, 2016–2017) and hospital characteristics (number of beds [<500 , ≥ 500] and hospital's location [Autonomous region]).

Statistical analysis

Descriptive analysis of patients' characteristics was carried out using frequency tables for categorical variables and median and interquartile range for continuous variables. Differences in socio-demographic and clinical characteristics according to initial regimen were assessed with the non-parametric Kruskal-Wallis test for continuous variables and the chi-squared test for independence for categorical variables. We used multivariable multinomial regression to estimate Relative Risk Ratios (RRRs) for the association between explanatory variables and the choice of the initial regimen. All variables that retained a significant independent association ($p < 0.05$) were included in the final model.

Heterogeneity introduced by different hospitals was accounted for by including the study hospital as a fixed effect in the model and by using robust methods to estimate standard errors and, thus, to calculate 95% confidence intervals and p-values.

All statistical analyses were performed using Stata software (version 15.0; Stata Corporation, College Station, Texas, USA).

Ethics

Ethics approval was obtained from all hospitals' Ethics' Committees and every patient provided written informed consent to participate in the cohort. This study was approved by the Ethics Committee of Instituto de Salud Carlos III (CEI PI 63_2017-v2).

Results

Between September 1, 2014 and November 30, 2017, 3,575 patients aged ≥ 18 years initiated treatment; among these, 147 (4.1%) with no follow-up after ART initiation and 554 (15.5%) who initiated a treatment prescribed in $< 5\%$ of patients were excluded. The final analysis included 2,874 (80.4%) subjects who initiated ART during the period of study. They were predominantly male (88.5%) and 59.7% were from Spain. Transmission route was heterosexual contact in 23.5% and MSM in 68.9%. At treatment initiation, median age was 36 years (interquartile range [IQR]: 30–44), median CD4+ T-cell count was 416 cells/ μL (IQR: 243–591), 8.5% of patients had a history of AIDS diagnosis, 34.5% had a viral load $> 100,000$ copies/mL and 89.2% were attending hospitals with more than 500 beds.

The most frequently prescribed initial regimens in the study period and the differences in sociodemographic and clinical characteristics of patients according to their initial ART regimen are shown in [Table 1](#). TDF/FTC+bDRV and TDF/FTC+RAL were significantly less often used in participants with upper education and among MSM. TAF/FTC/EVG/COBI was more likely prescribed among immigrants and TDF/FTC+RAL among those aged 50 years or older.

As expected, rilpivirine was rarely used in patients with high baseline viral load $> 100,000$ copies/mL (2.5%) or CD4 counts < 200 cells/ μL (4.0%). A higher proportion of the patients starting TDF/FTC+DTG, TDF/FTC+bDRV and TDF/FTC+RAL had a CD4 cell count below 200 cells/ μL and an AIDS diagnosis at start of treatment. TDF/FTC+DTG and TDF/FTC+RAL were more frequent in participants with triglycerides > 150 mg/dL and cholesterol-HDL ≤ 40 mg/dL. Large differences in the prescription of initial regimen were noted by hospital location but not by hospital size. There were also differences in the use of initial regimen in relation to HBVSA and previous cardiovascular event; nevertheless they must be interpreted with caution as the number of events was small.

We also observed changes over time in the distribution of the most frequent initial ART regimens ([Fig 1](#)). In the period 2014–2015, TDF/FTC/RPV (25.3%) and TDF/FTC/EVG/COBI (25.2%) were the most frequently prescribed initial ART, followed by ABC/3TC/DTG (21.6%). However, in the period 2016–2017, the most frequent regimen was ABC/3TC/DTG (40.0%), followed by TAF/FTC/EVG/COBI (23.8%). When grouping the regimens by their third agent, the only regimens whose prescription increased over time were the ones based in DTG (including ABC/3TC/DTG and TDF/FTC+DTG) and EVG (including TDF/FTC/EVG/COBI and TAF/FTC/EVG/COBI), while the prescription of all other regimens decreased. Regimens based in DTG increased from being prescribed in 29.1% of the patients in 2014–2015 to 51.8% in 2016–2017, and those based in EVG increased from 25.2% to 30.9%, respectively ([Fig 1](#)).

Results from multivariable analysis are shown in [Table 2](#). Compared with ABC/3TC/DTG, starting TDF/FTC/RPV was less likely in patients with CD4 counts < 200 cells/ μL (RRR, 95% CI: 0.41, 0.25–0.67) and with HIV-RNA $> 100,000$ copies/mL (RRR, 95% CI: 0.05, 0.03–0.10); inversely TDF/FTC+DTG was more frequent in those with CD4 counts < 200 cells/ μL (RRR, 95% CI: 3.35, 2.34–4.80) and with HIV-RNA $> 100,000$ copies/mL (RRR, 95% CI: 1.74, 1.21–2.52). TDF/FTC+RAL and TDF/FTC+bDRV were also more likely to be prescribed among patients with CD4 counts < 200 cells/ μL (RRR, 95% CI: 3.76, 2.39–5.92 and RRR, 95% CI: 2.61, 1.51–4.49, respectively) and those with transmission categories other than MSM (RRR, 95% CI: 2.00, 1.29–3.10 and RRR, 95% CI: 1.73, 1.14–2.61, respectively). Compared with ABC/3TC/DTG, the prescription of other initial ART regimens decreased over time ($p < 0.001$), with the exception of TDF/FTC+DTG ($p = 0.173$). Valid conclusions regarding changes over time in the prescription of TAF/FTC/EVG/COBI could not be drawn because it was widely available only after 2016. Overall differences in the choice of the initial ART regimen were observed

Table 1. Baseline characteristics of 2,874 study participants according to the initial antiretroviral regimen.

	ABC/3TC/DTG	TDF/FTC/EVG/COBI	TDF/FTC/RPV	TAF/FTC/EVG/COBI	TDF/FTC+DTG	TDF/FTC+bDRV	TDF/FTC+RAL	P
	923 (32.1%)	427 (14.9%)	401 (14.0%)	394 (13.7%)	287 (10.0%)	282 (9.8%)	160 (5.6%)	
Male sex	815 (88.3%)	393 (92.0%)	365 (91.0%)	345 (87.6%)	253 (88.2%)	248 (87.9%)	125 (78.1%)	<0.001
Upper education	518 (56.1%)	242 (56.7%)	215 (53.6%)	232 (58.9%)	155 (54.0%)	125 (44.3%)	70 (43.8%)	0.033
Immigrants	339 (36.7%)	172 (40.3%)	151 (37.7%)	191 (48.5%)	109 (38.0%)	101 (35.8%)	61 (38.1%)	0.003
Men who have sex with men	659 (71.4%)	324 (75.9%)	289 (72.1%)	278 (70.6%)	191 (66.6%)	154 (54.6%)	84 (52.5%)	<0.001
Age ≥50 years-old	117 (12.7%)	33 (7.7%)	40 (10.0%)	41 (10.4%)	45 (15.7%)	45 (16.0%)	31 (19.4%)	<0.001
AIDS	53 (5.7%)	28 (6.6%)	3 (0.7%)	19 (4.8%)	54 (18.8%)	41 (14.5%)	47 (29.4%)	<0.001
Median CD4 (IQR)	443 (283–609)	445 (274–590)	506 (378–719)	430 (265–591)	286 (94–473)	296 (111–492)	230 (72–449)	<0.001
CD4 count <200 cells/μL	120 (13.0%)	71 (16.6%)	16 (4.0%)	65 (16.5%)	107 (37.3%)	94 (33.3%)	68 (42.5%)	<0.001
Viral load >100,000 copies/mL	317 (34.3%)	147 (34.4%)	10 (2.5%)	154 (39.1%)	155 (54.0%)	131 (46.5%)	77 (48.1%)	<0.001
Triglycerides >150 mg/dL	154 (16.7%)	65 (15.2%)	54 (13.5%)	62 (15.7%)	69 (24.0%)	48 (17.0%)	39 (24.4%)	<0.001
HDL cholesterol ≤40 mg/dL	419 (45.4%)	147 (34.4%)	128 (31.9%)	168 (42.6%)	139 (48.4%)	129 (45.7%)	74 (46.3%)	<0.001
Total cholesterol >200 mg/dL	113 (12.2%)	49 (11.5%)	47 (11.7%)	49 (12.4%)	27 (9.4%)	32 (11.3%)	21 (13.1%)	0.941
HCV + antibody	46 (5.0%)	21 (4.9%)	23 (5.7%)	19 (4.8%)	16 (5.6%)	19 (6.7%)	14 (8.8%)	0.073
HBV S + antigen	3 (0.3%)	11 (2.6%)	13 (3.2%)	6 (1.5%)	12 (4.2%)	5 (1.8%)	5 (3.1%)	0.551
Cardiovascular event	14 (1.5%)	9 (2.1%)	5 (1.2%)	6 (1.5%)	9 (3.1%)	5 (1.8%)	11 (6.9%)	<0.001
Renal event	17 (1.8%)	10 (2.3%)	5 (1.2%)	8 (2.0%)	7 (2.4%)	3 (1.1%)	7 (4.4%)	0.258
Neurologic event	33 (3.6%)	14 (3.3%)	12 (3.0%)	8 (2.0%)	15 (5.2%)	8 (2.8%)	10 (6.3%)	0.151
Hospital size ≤ 500 beds	834 (90.4%)	377 (88.3%)	352 (87.8%)	340 (86.3%)	268 (93.4%)	250 (88.7%)	143 (89.4%)	0.081
Hospitals' location*								<0.001
A	123 (13.3%)	118 (27.6%)	67 (16.7%)	124 (31.5%)	22 (7.7%)	26 (9.2%)	17 (10.6%)	
B	2 (0.2%)	1 (0.2%)	3 (0.7%)	2 (0.5%)	0 (0.0%)	2 (0.7%)	0 (0.0%)	
C	11 (1.2%)	0 (0.0%)	5 (1.2%)	1 (0.3%)	6 (2.1%)	17 (6.0%)	0 (0.0%)	
D	9 (1.0%)	1 (0.2%)	2 (0.5%)	0 (0.0%)	4 (1.4%)	4 (1.4%)	0 (0.0%)	
E	87 (9.4%)	62 (14.5%)	36 (9.0%)	36 (9.1%)	16 (5.6%)	27 (9.6%)	18 (11.3%)	
F	22 (2.4%)	12 (2.8%)	19 (4.7%)	5 (1.3%)	5 (1.7%)	2 (0.7%)	6 (3.8%)	
G	104 (11.3%)	19 (4.4%)	21 (5.2%)	26 (6.6%)	9 (3.1%)	9 (3.2%)	0 (0.0%)	
H	22 (2.4%)	0 (0.0%)	7 (1.7%)	0 (0.0%)	20 (7.0%)	3 (1.1%)	1 (0.6%)	
I	407 (44.1%)	159 (37.2%)	131 (32.7%)	146 (37.1%)	138 (48.1%)	56 (19.9%)	49 (30.6%)	
J	40 (4.3%)	19 (4.4%)	6 (1.5%)	17 (4.3%)	26 (9.1%)	15 (5.3%)	6 (3.8%)	
K	25 (2.7%)	0 (0.0%)	12 (3.0%)	3 (0.8%)	0 (0.0%)	23 (8.2%)	21 (13.1%)	
L	5 (0.5%)	0 (0.0%)	56 (14.0%)	0 (0.0%)	0 (0.0%)	67 (23.8%)	32 (20.0%)	
M	66 (7.2%)	36 (8.4%)	36 (9.0%)	34 (8.6%)	41 (14.3%)	31 (11.0%)	10 (6.3%)	
Period of ART initiation-2016–17	657 (71.2%)	116 (27.2%)	89 (22.2%)	391 (99.2%)	194 (67.6%)	128 (45.4%)	67 (41.9%)	<0.001

*Each capital letter identifies one of the Autonomous Regions. The names of the Autonomous Regions cannot be disclosed due to confidentiality reasons

<https://doi.org/10.1371/journal.pone.0221598.t001>

by hospital's location. No other significant factors were found for the choice of TDF/FTC/EVG/COBI and TAF/FTC/EVG/COBI, compared to ABC/3TC/DTG.

Discussion

This is, to our knowledge, the first study assessing the factors influencing the choice of initial ART in a reasonable large cohort in recent years, when newer treatment regimens have




Fig 1. Distribution of the initial antiretroviral treatment by period of ART initiation.

<https://doi.org/10.1371/journal.pone.0221598.g001>

become widely available. All the regimens analyzed were considered preferred or alternative by the Spanish treatment guidelines during the study period [1,12–14], but our results suggest that the choice between different regimens could be influenced by certain characteristics of the patient or the hospitals where the treatment is initiated, in addition to the efficacy and toxicity results shown in clinical trials.

Overall, ABC/3TC/DTG was the most frequently prescribed regimen. Interestingly, the prescription of initial regimens changed over the calendar period. Over time, the prescription of regimens based in DTG and EVG increased. TDF/FTC/EVG/COBI prescription decreased but this was probably partly due to the introduction of TAF/FTC/EVG/COBI, which became available in Spain in 2016. The prescription of the other regimens (TDF/FTC/RPV, TDF/FTC+bDRV and TDF/FTC+RAL) decreased over time. These changes reflect those introduced in the Spanish HIV treatment guidelines. In 2014, all the regimens included in this study were considered preferred treatments [12]. However, since 2015 the guidelines became much more restrictive and have only recommended regimens based on integrase inhibitors as preferred, and have classified all the other regimens analyzed as alternative [1,13,14]. Despite being a preferred regimen, TDF/FTC+RAL was prescribed much less than the regimens based in DTG or EVG. This is probably due to the availability of these latter drugs as part of single tablet regimens.

Different regimens were preferentially prescribed to certain groups. The use of integrase inhibitors was more frequent among MSM. This could be in part due to patients' preference, as MSM frequently have more access to information about HIV [8] and could be more informed about new treatments (and request them to their physicians) than other risk groups.

TDF/FTC+RAL, TDF/FTC+bDRV and TDF/FTC+DTG were more likely to be prescribed to patients with low CD4 counts. The use of TDF/FTC is probably due to the need to initiate

Table 2. Multivariable relative risk ratios for predictors of the choice of the initial ART regimen relative to ABC/3TC/DTG.

	TDF/FTC/EVG/COBI		TDF/FTC/RPV		TAF/FTC/EVG/COBI		TDF/FTC+DTG		TDF/FTC+bDRV		TDF/FTC+RAL	
	RRR (IC 95%)	P	RRR (IC 95%)	P	RRR (IC 95%)	P	RRR (IC 95%)	P	RRR (IC 95%)	P	RRR (IC 95%)	P
HIV transmission category												
MSM	1		1		1		1		1		1	
Non-MSM	0.96 (0.67–1.39)	0.833	1.10 (0.79–1.54)	0.575	1.10 (0.78–1.54)	0.598	0.98 (0.69–1.38)	0.892	1.73 (1.14–2.61)	0.009	2.00 (1.29–3.10)	0.002
CD4 T-cell count												
>= 200 cells/μL	1		1		1		1		1		1	
<200 cells/μL	1.28 (0.97–1.70)	0.085	0.41 (0.25–0.67)	<0.001	1.18 (0.84–1.66)	0.331	3.35 (2.34–4.80)	<0.001	2.61 (1.51–4.49)	0.001	3.76 (2.39–5.92)	<0.001
Viral Load												
<= 100,000 cop/mL	1		1		1		1		1		1	
>100,000 cop/mL	1.03 (0.72–1.48)	0.869	0.05 (0.03–0.10)	<0.001	1.15 (0.87–1.52)	0.330	1.74 (1.21–2.52)	0.003	1.21 (0.84–1.75)	0.300	1.16 (0.70–1.91)	0.566
Period of ART initiation												
2014–2015	1		1		1		1		1		1	
2016–2017	0.17 (0.12–0.22)	<0.001	0.09 (0.05–0.15)	<0.001	NA		0.79 (0.57–1.11)	0.173	0.22 (0.12–0.42)	<0.001	0.23 (0.12–0.42)	<0.001
Hospitals' location*												
A	1		1		1		1		1		1	
B	1.17 (0.84–1.63)		7.02 (4.87–10.12)		0.57 (0.39–0.85)		NA		9.25 (4.43–19.32)		NA	
C	NA		2.06 (0.71–5.95)		0.05 (0.02–0.12)		3.96 (1.30–12.03)		10.54 (3.34–33.30)		NA	
D	0.22 (0.15–0.31)		0.98 (0.73–1.31)		NA		3.38 (1.85–6.18)		4.34 (2.14–8.79)		NA	
E	1.08 (0.57–2.04)		1.37 (0.35–5.42)		0.28 (0.16–0.51)		1.00 (0.39–2.55)		1.60 (0.45–5.64)		1.53 (0.69–3.40)	
F	0.70 (0.21–2.34)		2.12 (1.31–3.43)		0.18 (0.07–0.44)		1.28 (0.66–2.51)		0.43 (0.03–6.69)		1.78 (0.89–3.56)	
G	0.28 (0.21–0.39)		0.71 (0.55–0.93)		0.18 (0.12–0.27)		0.54 (0.31–0.93)		0.50 (0.27–0.92)		NA	
H	NA		1.10 (0.83–1.46)		NA		5.87 (3.38–10.17)		0.75 (0.39–1.42)		0.38 (0.18–0.78)	
I	0.60 (0.30–1.20)		1.08 (0.73–1.61)		0.26 (0.13–0.51)		2.01 (0.93–4.36)		0.85 (0.39–1.87)		1.15 (0.47–2.84)	
J	0.80 (0.39–1.66)		0.63 (0.32–1.21)		0.30 (0.12–0.74)		3.59 (1.45–8.86)		2.15 (1.06–4.35)		1.38 (0.42–4.53)	
K	NA		2.23 (1.61–3.08)		0.08 (0.05–0.12)		NA		5.12 (2.67–9.82)		6.97 (3.32–14.65)	
L	NA		78.87 (28.19–220.65)		NA		NA		101.92 (17.62–589.58)		71.74 (26.53–194.01)	
M	0.77 (0.25–2.43)		1.60 (0.60–4.27)		0.39 (0.15–1.01)		3.73 (1.49–9.33)		2.66 (0.73–9.74)		1.25 (0.32–4.88)	

*Each capital letter identifies one of the Autonomous Regions. The names of the Autonomous Regions cannot be disclosed due to confidentiality reasons

<https://doi.org/10.1371/journal.pone.0221598.t002>

treatment promptly when results from HLA B5701 are not yet available, and RAL and DTG could probably be used to minimize interactions in patients that might be being treated for other opportunistic diseases. Also, prevalence of resistance to integrase inhibitors is low in Spain [15,16] and these agents are frequently prescribed when resistance tests are still pending. The prescription of TDF/FTC+bDRV for patients with low CD4 counts reached borderline statistical significance, probably due to the high genetic barrier of protease inhibitors that allows their use in severely immunosuppressed patients while waiting for resistance test results, as described in earlier studies[5].

The choice of regimens varied significantly by hospital location. This is not explained by local variations in clinical characteristics of the patients, as these differences were still large after adjusting for all other factors. Possible explanations include regional variations on the physicians' perceptions of efficacy and safety of different regimens[17], different experience on HIV treatment among the treating physicians, and institutional constraints. Although we could not assess limitations to ART prescription in all the participating hospitals for the study period, we have recently described the limitations for the prescription of antiretrovirals in the CoRIS cohort for the period 2010–2015: 54.1% of the centres had a cost limitation for the prescription of ART and 29.7% had restricted access to at least one antiretroviral or single-tablet regimen (mainly some of the newest integrase inhibitors)[18,19]. Although we could not analyze the influence of institutional constraints in the results of this study, it is possible that they could have an influence in the choice of the initial ART: our previous study demonstrated that hospitals with restricted access to at least one antiretroviral were more likely to prescribe ART regimens that were not recommended by the Spanish clinical guidelines[19].

Our study is limited by the lack of information on individual physician's characteristics, and some clinical variables that could influence the choice of ART such as pregnancy, resistance testing or other drugs that could interact with ART. However, our strengths include the analysis of a reasonably large number of patients from a multicenter well established cohort, and the recent time period which allow us to analyze the newer treatment regimens. Our results suggest that initial ART prescriptions are influenced by clinical and demographic patient variables, and also by the prescribing hospital location.

In conclusion, in this multicenter Spanish cohort the prescription of initial ART regimens varied not only with patients' clinical and demographic characteristics, but also with other variables such as the period of ART initiation and hospital location. Over time, regimens based on integrase inhibitors have become the most frequent choice as initial ART.

Acknowledgments

This study would not have been possible without the collaboration of all patients, medical and nursery staff and data managers who have taken part in the project.

Centers and investigators involved in CoRIS

Executive committee: Santiago Moreno, Inma Jarrín, David Dalmau, Maria Luisa Navarro, Maria Isabel González, Jose Luis Blanco, Federico Garcia, Rafael Rubio, Jose Antonio Iribarren, Félix Gutiérrez, Francesc Vidal, Juan Berenguer, Juan González.

Fieldwork, data management and analysis: Belén Alejos, Victoria Hernando, Cristina Moreno, Carlos Iniesta, Luis Miguel Garcia Sousa, Nieves Sanz Perez

BioBanK HIV: Hospital General Universitario Gregorio Marañón: M Ángeles Muñoz-Fernández, Isabel María García-Merino, Irene Consuegra Fernández, Coral Gómez Rico, Jorge Gallego de la Fuente, Paula Palau Concejo.

Participating centres:

Hospital General Universitario de Alicante (Alicante): Joaquín Portilla, Esperanza Merino, Sergio Reus, Vicente Boix, Livia Giner, Carmen Gadea, Irene Portilla, María Pampliega, Marcos Díez, Juan Carlos Rodríguez, José Sánchez-Payá.

Hospital Universitario de Canarias (San Cristobal de la Laguna): Juan Luis Gómez, Johovana Hernández, María Remedios Alemán, María del Mar Alonso, María Inmaculada Hernández, Felicitas Díaz-Flores, Dácil García, Ricardo Pelazas., Ana López Lirola

Hospital Universitario Central de Asturias (Oviedo): José Sanz Moreno, Alberto Arranz Caso, Cristina Hernández Gutiérrez, María Novella Mena

Hospital Universitario 12 de Octubre (Madrid): Rafael Rubio, Federico Pulido, Otilia Bisbal, Asunción Hernando, Lourdes Domínguez, David Rial Crestelo, Laura Bermejo, Mireia Santacreu.

Hospital Universitario de Donostia (Donostia-San Sebastián): José Antonio Iribarren, Julio Arrizabalaga, María José Aramburu, Xabier Camino, Francisco Rodríguez-Arondo, Miguel Ángel von Wichmann, Lidia Pascual Tomé, Miguel Ángel Goenaga, M^a Jesús Bustinduy, Harkaitz Azkune, Maialen Iburguren, Aitziber Lizardi, Xabier Kortajarena.

Hospital General Universitario De Elche (Elche): Félix Gutiérrez, Mar Masiá, Sergio Padilla, Andrés Navarro, Fernando Montolio, Catalina Robledano, Joan Gregori Colomé, Araceli Adsuar, Rafael Pascual, Marta Fernández, Elena García., José Alberto García, Xavier Barber.

Hospital Universitari Germans Trias i Pujol (Can Ruti) (Badalona): Roberto Muga, Arantza Sanvisens, Daniel Fuster.

Hospital General Universitario Gregorio Marañón (Madrid): Juan Berenguer, Juan Carlos López Bernaldo de Quirós, Isabel Gutiérrez, Margarita Ramírez, Belén Padilla, Paloma Gijón, Teresa Aldamiz-Echevarría, Francisco Tejerina, Francisco José Parras, Pascual Balsalobre, Cristina Díez, Leire Pérez Latorre.

Hospital Universitari de Tarragona Joan XXIII (Tarragona): Francesc Vidal, Joaquín Peraire, Consuelo Viladés, Sergio Veloso, Montserrat Vargas, Miguel López-Dupla, Montserrat Olona, Anna Rull, Esther Rodríguez-Gallego, Verónica Alba.

Hospital Universitario y Politécnico de La Fe (Valencia): Marta Montero Alonso, José López Aldeguer, Marino Blanes Juliá, María Tacias Pitarch, Iván Castro Hernández, Eva Calabuig Muñoz, Sandra Cuéllar Tovar, Miguel Salavert Lletí, Juan Fernández Navarro.

Hospital Universitario La Paz/IdiPAZ: Juan González-garcía, Francisco Arnalich, José Ramón Arribas, Jose Ignacio Bernardino de la Serna, Juan Miguel Castro, Luis Escosa, Pedro Herranz, Victor Hontañón, Silvia García-Bujalance, Milagros García López-Hortelano, Alicia González-Baeza, Maria Luz Martín-Carbonero, Mario Mayoral, Maria Jose Mellado, Rafael Esteban Micán, Rocio Montejano, María Luisa Montes, Victoria Moreno, Ignacio Pérez-Valero, Berta Rodés, Talia Sainz, Elena Sendagorta, Natalia Stella Alcáriz, Eulalia Valencia.

Hospital San Pedro Centro de Investigación Biomédica de La Rioja (CIBIR) (Logroño): José Ramón Blanco, José Antonio Oteo, Valvanera Ibarra, Luis Metola, Mercedes Sanz, Laura Pérez-Martínez.

Hospital Universitario Miguel Servet (Zaragoza): Piedad Arazo, Gloria Sampérez.

Hospital Universitari MutuaTerrassa (Terrasa): David Dalmau, Angels Jaén, Montse Sanmartí, Mireia Cairó, Javier Martínez-Lacasa, Pablo Velli, Roser Font, Mariona Xercavins, Noemí Alonso.

Complejo Hospitalario de Navarra (Pamplona) María Rivero, Jesús Repáraz, María Gracia Ruiz de Alda, María Teresa de León Cano, Beatriz Pierola Ruiz de Galarreta.

Corporació Sanitària Parc Taulí (Sabadell): Ferrán Segura, María José Amengual, Gemma Navarro, Montserrat Sala, Manuel Cervantes, Valentín Pineda, Sonia Calzado, Marta Navarro.

Hospital Universitario de La Princesa (Madrid): Ignacio de los Santos, Jesús Sanz Sanz, Ana Salas Aparicio, Cristina Sarriá Cepeda, Lucio García-Fraile Fraile, Enrique Martín Gayo.

Hospital Universitario Ramón y Cajal (Madrid): Santiago Moreno, José Luis Casado, Fernando Dronza, Ana Moreno, María Jesús Pérez Elías, Cristina Gómez Ayerbe, Carolina Gutiérrez, Nadia Madrid, Santos del Campo Terrón, Paloma Martí, Uxua Ansa, Sergio Serano, María Jesús Vivancos.

Hospital General Universitario Reina Sofía (Murcia) Enrique Bernal, Alfredo Cano, Antonia Alcaraz García, Joaquín Bravo Urbieto, Ángeles Muñoz, Maria Jose Alcaraz, Maria del Carmen Villalba.

Hospital Nuevo San Cecilio (Granada): Federico García, José Hernández, Alejandro Peña, Leopoldo Muñoz, Paz Casas, Marta Alvarez, Natalia Chueca, David Vinuesa, Clara Martinez-Montes.

Centro Sanitario Sandoval (Madrid): Jorge Del Romero, Carmen Rodríguez, Teresa Puerta, Juan Carlos Carrió, Mar Vera, Juan Ballesteros, Oskar Ayerdi.

Hospital Clínico Universitario de Santiago (Santiago de Compostela): Antonio Antela, Elena Losada.

Hospital Universitario Son Espases (Palma de Mallorca): Melchor Riera, María Peñaranda, María Leyes, M^a Angels Ribas, Antoni A Campins, Carmen Vidal, Francisco Fanjul, Javier Murillas, Francisco Homar.

Hospital Universitario Virgen de la Victoria (Málaga): Jesús Santos, Crisitina Gómez Ayerbe, Isabel Viciano, Rosario Palacios, Carmen María González.

Hospital Universitario Virgen del Rocío (Sevilla): Pompeyo Viciano, Nuria Espinosa, Luis Fernando López-Cortés.

Hospital Universitario de Bellvitge (Hospitalet de Llobregat): Daniel Podzamczar, Elena Ferrer, Arkaitz Imaz, Juan Tiraboschi, Ana Silva, María Saumoy.

Hospital Universitario Valle de Hebrón (Barcelona): Esteban Ribera, Adrian Curran.

Hospital Costa del Sol (Marbella): Julián Olalla, Alfonso del Arco, Javier de la torre, José Luis Prada, José María García de Lomas Guerrero, Javier Pérez Stachowski.

Hospital General Universitario Santa Lucía (Cartagena): Onofre Juan Martínez, Francisco Jesús Vera, Lorena Martínez, Josefina García, Begoña Alcaraz, Amaya Jimeno.

Complejo Hospitalario Universitario a Coruña (Chuac) (A Coruña): Angeles Castro Iglesias, Berta Pernas Souto, Alvaro Mena de Cea.

Hospital Universitario Basurto (Bilbao): Josefa Muñoz, Miren Zuriñe Zubero, Josu Mirena Baraia-Etxaburu, Sofía Ibarra Ugarte, Oscar Luis Ferrero Beneitez, Josefina López de Munain, M^a Mar Cámara López, Mireia de la Peña, Miriam Lopez.

Hospital Universitario Virgen de la Arrixaca (El Palmar): Carlos Galera, Helena Alben-din, Aurora Pérez, Asunción Iborra, Antonio Moreno, Maria Angustias Merlos, Asunción Vidal.

Hospital de la Marina Baixa (La Vila Joiosa): Concha Amador, Francisco Pasquau, Javier Ena, Concha Benito, Vicenta Fenoll., Concepcion Gil Anguita, Jose Tomas Algado Rabasa.

Hospital Universitario Infanta Sofia (San Sebastian de los Reyes): Inés Suárez-García, Eduardo Malmierca, Patricia González-Ruano, Dolores Martín Rodrigo, M^a Pilar Ruiz Seco.

Complejo Hospitalario de Jaén (Jaén) Mohamed Omar Mohamed-Balghata, María Amparo Gómez Vidal.

Hospital San Agustín (Avilés): Miguel Alberto de Zarraga.

Hospital Clínico San Carlos (Madrid): Vicente Estrada Pérez, Maria Jesus Téllez Molina, Jorge Vergas García, Juncal Pérez-Somarriba Moreno.

Hospital Universitario Fundación Jiménez Díaz (Madrid): Miguel Górgolas., Alfonso Cabello., Beatriz Álvarez., Laura Prieto.

Hospital Universitario Príncipe de Asturias (Alcalá de Henares): José Sanz Moreno, Alberto Arranz Caso, Cristina Hernández Gutiérrez, María Novella Mena.

Hospital Clínico Universitario de Valencia (València): María José Galindo Puerto, Ramón Fernando Vilalta, Ana Ferrer Ribera.

Hospital Reina Sofía (Córdoba): Antonio Rivero Román, María Teresa Brieva Herrero, Antonio Rivero Juárez, Pedro López López, Isabel Machuca Sánchez, José Peña Martínez.

Hospital Universitario Severo Ochoa (Leganés): Miguel Cervero Jiménez, Rafael Torres Perea, Juan José Jusdado Ruiz-Capillas.

Nuestra Señora de Valme: Juan A Pineda.

Author Contributions

Conceptualization: Santiago Moreno, Inma Jarrín.

Data curation: Belén Alejos, Inés Suárez-García, Otilia Bisbal, José Antonio Iribarren, Víctor Asensi, Miguel Górgolas, Roberto Muga.

Formal analysis: Belén Alejos.

Funding acquisition: Santiago Moreno, Inma Jarrín.

Investigation: Belén Alejos, Inés Suárez-García, Otilia Bisbal, José Antonio Iribarren, Víctor Asensi, Miguel Górgolas, Roberto Muga.

Methodology: Belén Alejos, Santiago Moreno, Inma Jarrín.

Project administration: Inma Jarrín.

Supervision: Santiago Moreno, Inma Jarrín.

Writing – original draft: Belén Alejos, Inés Suárez-García.

Writing – review & editing: Belén Alejos, Inés Suárez-García, Otilia Bisbal, José Antonio Iribarren, Víctor Asensi, Miguel Górgolas, Roberto Muga, Santiago Moreno, Inma Jarrín.

References

1. Panel de expertos de Gesida y Plan Nacional sobre el SIDA (2017) Documento de consenso de GeSIDA/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana (Actualización enero 2017).
2. European AIDS Clinical Society (2017) EACS Guidelines. Version 9.0. October 2017.
3. Pannel on Antiretroviral Guidelines for Adults and Adolescents Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV (update October 25, 2018). Department of Health and Human Services.
4. GeSIDA/Plan Nacional sobre el SIDA Documento de consenso de GeSIDA/Plan Nacional sobre el SIDA respecto al tratamiento antirretroviral en adultos infectados por del virus de la inmunodeficiencia humana (actualización Enero 2018).
5. Viciano P, Ocampo A, Hevia H, Palazuelos M, Ledesma F (2014) [Initial antiretroviral treatment in human immunodeficiency virus-infected patients in Spain: Decisions made in relation to particular immunovirological characteristics (PERFIL-es study)]. *Enferm Infecc Microbiol Clin* 32: 93–95. <https://doi.org/10.1016/j.eimc.2013.08.002> PMID: 24144784
6. Hata M, Redlin SE, Nelson M (2015) Factors influencing combination antiretroviral therapy choice: Do doctors really know best? *J Infect* 71: 269–271. <https://doi.org/10.1016/j.jinf.2015.03.005> PMID: 25818533
7. Elzi L, Erb S, Furrer H, Ledergerber B, Cavassini M, Hirschel B, et al. (2012) Choice of Initial Combination Antiretroviral Therapy in Individuals With HIV Infection: Determinants and Outcomes. *Arch Intern Med* 172: 1313–1321. <https://doi.org/10.1001/archinternmed.2012.3216> PMID: 22892835
8. Viciano P, Ocampo A, Hevia H, Palazuelos M, Ledesma F (2016) Sociodemographic and clinical factors associated with the preference between NNRTIs and PIs for the initial treatment of HIV infection: Perfil-

- es study. *AIDS Care* 28: 1321–1326. <https://doi.org/10.1080/09540121.2016.1173640> PMID: 27140483
9. Rouveix E, Mortier E, Beauchet A, Dupont C, Gerbe J, Daneluzzi V, et al. (2016) [Choice of initial regimen for antiretroviral-naive HIV patients: Analysis of motivation]. *Rev Med Interne* 37: 796–801. <https://doi.org/10.1016/j.revmed.2016.05.018> PMID: 27372517
 10. Caro-Murillo AM, Castilla J, Perez-Hoyos S, Miro JM, Podzamczar D, Rubio R, et al. (2007) [Spanish cohort of naive HIV-infected patients (CoRIS): rationale, organization and initial results]. *Enferm Infecc Microbiol Clin* 25: 23–31. PMID: 17261243
 11. Sobrino-Vegas P, Gutierrez F, Berenguer J, Labarga P, Garcia F, Alejos-Ferreras B, et al. (2011) [The Cohort of the Spanish HIV Research Network (CoRIS) and its associated biobank; organizational issues, main findings and losses to follow-up]. *Enferm Infecc Microbiol Clin* 29: 645–653. <https://doi.org/10.1016/j.eimc.2011.06.002> PMID: 21820763
 12. (2014) [GeSIDA/National AIDS Plan: Consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (Updated January 2014)]. *Enferm Infecc Microbiol Clin* 32: 446 e441–442.
 13. (2015) [GESIDA/National AIDS Plan: Consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (Updated January 2015)]. *Enferm Infecc Microbiol Clin* 33: 543 e541–543.
 14. Panel de expertos de Gesida y Plan Nacional sobre el SIDA Documento de consenso de GeSIDA/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana (Actualización enero 2016).
 15. Gutierrez C, Hernandez-Novoa B, Perez-Elias MJ, Moreno AM, Holguin A, Dronda F, et al. (2013) Prevalence of primary resistance mutations to integrase inhibitors in treatment-naive and -experienced patients infected with B and non-B HIV-1 variants. *HIV Clin Trials* 14: 10–16. <https://doi.org/10.1410/hct1401-10> PMID: 23372110
 16. Casadella M, van Ham PM, Noguera-Julian M, van Kessel A, Pou C, Hofstra LM, et al. (2015) Primary resistance to integrase strand-transfer inhibitors in Europe. *J Antimicrob Chemother* 70: 2885–2888. <https://doi.org/10.1093/jac/dkv202> PMID: 26188038
 17. Kuritzkes DR (2012) An Abundance of Choices: Comment on "Choice of Initial Combination Antiretroviral Therapy in Individuals With HIV Infection: Determinants and Outcomes". *Arch Intern Med* 172: 1321–1323. <https://doi.org/10.1001/archinternmed.2012.3644> PMID: 22892875
 18. Suárez-García I, González J, Berenguer J, Garcia F, Portilla J, Muga R, et al. (2018) Cost limitations and restricted access to antiretroviral drugs as potential barriers for compliance to HIV treatment guidelines in the CoRIS cohort. X Conference of the Spanish AIDS Study Group (GeSIDA). Madrid.
 19. Suarez-Garcia I, Gonzalez J, Berenguer J, Garcia F, Portilla J, Muga R, et al. (2019) Reasons for non-compliance with the national guidelines for initial antiretroviral therapy of HIV-infected patients in Spain, 2010–2015. *Enferm Infecc Microbiol Clin*.